Prof. Dr. Martina Düfer
Topics of research
|
Topics of research
|
In view of the permanent increase in patients developing type 2 diabetes mellitus understanding of and interference with pathophysiological changes in the endocrine pancreas is very important. Intracellular Ca2+ is an essential messenger for physiological regulation of insulin secretion, but severely disturbs beta-cell function in case of misrouted balance or Ca2+ overload. Small molecules modulating Ca2+ influx itself or the effect of intracellular Ca2+ on other ion channels are promising compounds to either preserve beta-cell response, thereby extenuating disease progression, or to promote hormone secretion in the light of increased demand. NMDA receptors are currently under investigation as novel targets to influence insulin secretion. GluN2A or B subunits of the channel tetramer are responsible for high Ca2+ conductance. Expression of these subunits is reported for insulin-secreting cell lines and rat islets Our previous work showed that KCa-regulated channels of large (“BK channels”) and intermediate conductance (KCa3.1, “IK1 channels”) both influence beta-cells, but only the inhibition of KCa3.1 channels potentiates nutrient-stimulated insulin release. At present, it is unclear whether KCa3.1 is localised solely in the plasma membrane of beta-cells or also in intracellular organelles, e.g. mitochondria, as is known for other cells. Furthermore, the effects of diabetes on distribution or function of these channels are not known.
This project aims to clarify the regulatory role of KCa3.1 channels and NMDA receptors for Ca2+ homeostasis and to elucidate the potential of subtype-specific modulators for improvement of beta-cell function.
Short biography |
|
2012 - present |
Full professor, Pharmacology and Toxicology, Institute of Pharmaceutical and Medicinal Chemistry, Dept. of Pharmacology, Westphalian Wilhelms University of Münster, Germany |
2010 |
Temporary professorship, Pharmacology and Toxicology, Institute of Pharmacy, Martin-Luther University of Halle, Germany |
2007 - 2012 |
Senior scientist (Akademische Rätin) and group leader, Dept. of Pharmacology, Clinical Pharmacy and Toxicology, Eberhard Karls University of Tübingen, Germany |
2006 |
Habilitation (Venia legendi: Pharmacology and Toxicology) |
2004 - 2007 |
Fellow of the Deutsche Forschungsgemeinschaft, Institute of Pharmacy, Eberhard Karls University of Tübingen, Germany |
2001 - 2004 |
Postdoctoral research fellow (group of Prof. Dr. G. Drews), Institute of Pharmacy, Dept. of Pharmacology, Clinical Pharmacy and Toxicology, Eberhard Karls University of Tübingen, Germany |
1997 - 2001 |
Ph. D. studies (group of Prof. Dr. G. Drews), Institute of Pharmacy, Dept. of Pharmacology, Clinical Pharmacy and Toxikology, Eberhard Karls University of Tübingen, Germany |
1997 |
Approbation, licence to practice as Pharmacist |
1996 - 1997 |
Job training (practical year) at Boehringer Mannheim GmbH / Roche Diagnostics, Mannheim and at Zerrenner-Apotheke Pforzheim, Germany |
1991 - 1996 |
Studies of pharmacy, Ruprecht-Karls University of Heidelberg, Germany |
Scientific awards and appointments |
|
2017 - present |
Board member of the “Center for Teaching in Higher Education” (Zentrum für Hochschullehre, ZHL), Universität Münster |
2012 |
Call for a W2-professorship “Molecular Pharmacology”, Faculty of Medicine, Friedrich-Schiller University of Jena, Germany (declined) |
2011 |
Ferdinand Bertram Award of the DDG (Deutsche Diabetes Gesellschaft) |
1999 - 2001 |
Scholarship of the Landesgraduiertenförderung Baden-Württemberg |
1998 |
Poster Award, Section „Pharmacology“, DGPT (Deutsche Gesellschaft für Pharmakologie und Toxikologie) |
Memberships in scientific organisations |
European Association for the Study of Diabetes (EASD) |
Deutsche Pharmazeutische Gesellschaft (DPhG) |
Deutsche Physiologische Gesellschaft (DPG) |
Deutsche Diabetes Gesellschaft (DDG) |